Race Oncology

🇧🇪Belgium

Country: 🇧🇪Belgium

Ownership: -

Employees: -

Market Cap: $190.9M

Website

Clinical Trials

A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS

Phase 1

Withdrawn

Conditions: Acute Myeloid Leukemia
Recurrent Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia
Higher Risk Myelodysplastic Syndrome
Chronic Myelomonocytic Leukemia

Interventions: Drug: Bisantrene Dihydrochloride (high dose)
Drug: Bisantrene Dihydrochloride (low dose)
Drug: Cytarabine Hydrochloride
Drug: Decitabine and cedazuridine

First Posted Date: 2022-07-13

Last Posted Date: 2023-10-03

Lead Sponsor: Race Oncology Ltd

Registration Number: NCT05456269

Locations: 🇦🇺
Calvary Mater, Newcastle, New South Wales, Australia

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy